Akebia Therapeutics (AKBA) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Akebia Therapeutics (AKBA) has outperformed Sionna Therapeutics (SION) over the past year, losing 71.4% versus a loss of 83.2%. Akebia Therapeutics is the larger company by market cap ($225.8 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AKBA | SION |
|---|---|---|
| Share price | $0.8148 | $4.90 |
| Market cap | $225.79M | $221.24M |
| 1-day change | -6.71% | +1.66% |
| YTD return | -49.39% | -88.28% |
| 1-year return | -71.41% | -83.15% |
| 5-year return | -71.41% | — |
| EPS (TTM) | $-0.12 | $-2.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.20 | $54.97 |
| 52-week low | $0.814 | $4.01 |
| Distance from 52-week high | -74.54% | -91.09% |
| Analyst consensus | none | hold |
| Avg. price target upside | +381.10% | +328.57% |
| Average volume | 6.13M | 2.19M |
| Shares outstanding | 277.11M | 45.15M |
| Employees | 194 | 59 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AKBA has outperformed SION by 11.7 percentage points over the past year.
About Akebia Therapeutics
AKBA stock →Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD.
Health Care · Biotechnology: Pharmaceutical Preparations · 194 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
AKBA vs SION FAQ
Which is bigger, Akebia Therapeutics or Sionna Therapeutics?
Akebia Therapeutics (AKBA) is larger, with a market capitalization of $225.79M compared with $221.24M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, AKBA or SION?
AKBA returned -71.41% over the past 12 months, compared with -83.15% for SION (price return, excluding dividends). Past performance does not predict future results.
Are Akebia Therapeutics and Sionna Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.